MISSISSAUGA, Ontario--(BUSINESS WIRE)--Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for DESCOVY® (emtricitabine 200 mg and ...
Descovy and Truvada each have a Boxed Warning in their respective product labels regarding the risk of post-treatment acute exacerbation of hepatitis B; the Truvada label also carries a Boxed Warning ...
BOSTON--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today presented longer-term results from the DISCOVER trial of Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets, ...
Add Yahoo as a preferred source to see more of our stories on Google. A major health insurer has notified policy holders that it will no longer cover Gilead Sciences’ drug Descovy for pre-exposure ...
-- Submission supported by data from the DISCOVER trial, which evaluated the safety and efficacy of Descovy® compared to Truvada® in people at risk for sexually acquired HIV-1 infection -- MISSISSAUGA ...
When Gilead Sciences won Food and Drug Administration approval in October for a second drug to prevent HIV infection, some experts suggested that the drug it already had on the market would be ...
The federal Food and Drug Administration October 3 approved a new daily PrEP pill that could offer a safer option for some individuals at risk for HIV, but the indication does not cover everyone who ...
George Froehle, PA, a primary care clinician at CentraCare in rural St. Cloud, Minnesota, has been prescribing the HIV prevention pill tenofovir disoproxil fumarate plus emtracitabine (TDF/FTC) since ...
-- PrEP is part of the ongoing efforts by Gilead Canada to end the HIV epidemic-- MISSISSAUGA, ON, Dec. 1, 2020 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results